Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial CarcinomaGlobeNewsWire • 09/03/19
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/02/19
Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goalMarket Watch • 06/14/19
Kura Oncology's (KURA) CEO Troy Wilson on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/08/19